ALK
Manufacturing · Denmark · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Bøge Allé 6-8, Korsholm, North Denmark, ...Phone Number
+45 45747576Website
www.alk.netRevenue
$955.8 MillionStock Symbol
ALK-BIndustry
About ALK
ALK Org Chart
Is ALK your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
ALK, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when ALK launches new products
Congratulate Masked Content for being promoted to Masked Content at ALK
Check out if ALK is spiking on competitors!
Check if ALK has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if ALK had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on ALK recently announced quarterly report
Funding: Get notified immidiatlly once ALK has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
ALK is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ALK is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ALK.
ALK Tech Stack
A closer look at the technologies used by ALK
Most Recent Scoops
ALK News & Media
Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap
New scientific data reveal serious shortcomings in the real-world management of anaphylaxis, with findings from two multi-country surveys suggesting that EURneffy®—the first and only approved needle-free adrenaline-based product—may help address some of the practical and psychological challenges that limit effective emergency treatment in daily life.1,2 The data generated by ALK were presented at the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress in Istanbul, TuALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026
At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which will this year take part in Istanbul, Türkiye from 12 to 15 June 2026, the Danish pharmaceutical company ALK will present data and key insights within anaphylaxis, food and respiratory allergy.Alaska Air Group, Inc. (ALK) Presents at TD Cowen 10th Annual Future of the Consumer Conference Transcript
Alaska Air Group, Inc. (ALK) TD Cowen 10th Annual Future of the Consumer Conference June 3, 2026 8:45 AM EDTCompany ParticipantsShane Tackett - CFO &...Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff:
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ALK
ALK-Abelló is a global pharmaceutical company specializing in allergy immunotherapy treatments and diagnostics. Based in Denmark, the company develops, manufactures, and markets allergy vaccines and diagnostic products for the prevention and treatment of allergies. ALK focuses on sublingual and subcutaneous immunotherapy solutions that address resp... Read More